Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia

Journal of Urology

Volumn 163, Issue 5, 2000, Pages 1451-1456

  Marks, Leonard S ^a   Partin, Alan W ^a   Epstein, Jonathan I ^a   Tyler, Varro E ^a   Simon, Inpakala ^a   Macairan, Maria L ^a   Chan, Theresa L ^a   Dorey, Frederick J ^a   Garris, Joel B ^a   Veltri, Robert W ^a   Santos, Paul Bryan C ^a   Stonebrook, Kerry A ^a   DeKernion, Jean B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Medicine, herbal; Prostate; Prostatic hyperplasia

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; ESTRADIOL; HERBACEOUS AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; SEX HORMONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; HERBAL MEDICINE; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; TREATMENT OUTCOME; URINE VOLUME; UROFLOWMETRY;

EID: 18144436109     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67641-0     Document Type: Article

References (23)

1. Marks, L. S. and Tyler, V. E.: Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia. Urology, 53: 457, 1999
2. Wilt, T. J., Ishani, A., Stark, G. et al: Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA, 280: 1604, 1998
3. Buck, A. C.: Phytotherapy for the prostate. Brit J Urol, 78: 325, 1996
4. Lowe, F. C. and Ku, J. C.: Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology, 48: 12, 1996
5. Lowe, F. C. and Fagelman, E.: Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology, 53: 671, 1999
6. Marks, L. S., Partin, A. W., Gormley, G. J. et al: Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol, 157: 2171, 1997
7. Marks, L. S., Partin, A. W., Dorey, F. J. et al: Long-term effects of finasteride on prostate tissue composition. Urology, 53: 574, 1999
8. Hodge, K. K., McNeal, J. E., Terris, M. K. et al: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol, 142: 71, 1989
9. Kyprianou, N., Litvak, J. P., Borkowski, A. et al: Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol, 159: 1810, 1998
10. Bostwick, D. G., Wheeler, T. M., Blute, M. et al: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology, 48: 47, 1996
11. Perry, K. T., Anthony C. T. and Steiner, M. S.: Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate, 33: 133, 1997
12. Prins, G. S., Sklarew, R. J. and Pertschuk, L. P.: Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J Urol, 159: 641, 1998
13. Carraro, J.-C., Raynaud, J.-P., Koch, G. et al: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1098 patients. Prostate, 29: 231, 1996
14. Eisenberg, D. M., Davis, R. B., Ettner, S. L. et al: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA, 280: 1569, 1998
15. Rhodes, L., Primka, R. L., Berman, C. et al: Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition. Prostate, 22: 43, 1993
16. Strauch, G., Perles, P., Vergult, G. et al: Comparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol, 26: 247, 1994
17. Weisser, H., Behnke, B., Helpap, B. et al: Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol, 31: 97, 1997
18. Helpap, B., Oehler, U., Weisser, H. et al: Morphology of benign prostatic hyperplasia after treatment with Sabal extract IDS 89 or placebo J Urol Pathol, 3: 175, 1995
19. Gerber, G. S., Bales, G., Kirsh, E. et al: Medicinal botanicals in the treatment of lower urinary tract symptoms (LUTS): a demographic analysis of awareness and use at the University of Chicago. J Urol, suppl., 159: 334, abstract 1282, 1998
20. Nam, R. K., Fleshner, N., Rakovitch, E. et al: Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol, 161: 1521, 1999
21. Angell, M. and Kassirer, J. P.: Alternative medicine - the risks of untested and unregulated remedies. N Engl J Med, 339: 839, 1998
22. Dietary Supplement Health and Education Act of 1994. Public Law 103-417.
23. Slifman, N. R., Obermeyer, W. R., Aloi, B. K. et al: Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med, 339: 806, 1998